KEPHERA DIAGNOSTICS LLC
Framingham, MA · Medtech · Private
Point-of-care diagnostic test for Chagas disease using improved antigens to detect Trypanosoma cruzi infection
kephera.com →- Grants
- $27M
- 39 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $3.3M
- 6 awards · Health and Human S
- #156 of 4531 in medtech
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $299,621 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $598,136 | |
| Federal grant | Department of Health and Human Services · Phase I · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $298,515 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $299,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $599,316 | |
| Federal contract | Department of Health and Human Services · SBIR Phase 1 - Topic 39 Finding Human Carriers Of Taeniasis To Prevent Neurocysticercosis Assoc W/epilepsy | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $299,829 | |
| Federal grant | Department of Health and Human Services · Phase I · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $299,317 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Biomarker-Based Test of Cure for Chagas Disease | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Biomarker-Based Test of Cure for Chagas Disease | $600,000 | |
| Federal contract | Department of Health and Human Services · SBIR Phase I Award Topic 388: Screening And Point Of Care Diagnostic Assays For Opisthorchis Viverrini And Clonorchis Sinensis | $299,997 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase I · Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $299,829 | |
| Federal grant | Department of Health and Human Services · Phase I · Biomarker-Based Test of Cure for Chagas Disease | $300,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $1,989,300 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $989,300 | |
| Federal contract | Department of Health and Human Services · Develop A Biomarker-based Test Of Cure (toc) To Evaluate Treatment Outcome During The Chronic Phase Of Chagas Infection. | $300,000 | |
| Federal contract | Department of Health and Human Services · Topic 388: In Vitro Diagnostic For The Liver Flukes Opisthorchis Viverrini And Clonorchis Sinensi | $1,999,961 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an ELISA for serosurveillance of human hookworm | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1,020,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1,020,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of an ELISA for serosurveillance of human hookworm | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $999,008 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Biomarker-Based Test of Cure for Chagas Disease | $1,014,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Biomarker-Based Test of Cure for Chagas Disease | $1,014,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $1,025,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1,015,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an ELISA for serosurveillance of human hookworm | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Diagnostic assay for congenital Chagas disease | $303,250 | |
| Federal grant | Department of Health and Human Services · Phase II · Biomarker-Based Test of Cure for Chagas Disease | $1,013,849 | |
| Federal grant | Department of Health and Human Services · Phase II · Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $1,025,000 | |
| Federal grant | Department of Health and Human Services · Phase I · MiCRIA: Two-minute rapid assay platform for point-of-care diagnosis | $303,250 | |
| Federal contract | Department of Health and Human Services · SBIR 133 - Kephera | $300,000 | |
| Federal contract | Department of Health and Human Services · Novel Diagnostic Biomarkers Discovery And Validation For Malaria And Select Neglected Tropical Diseases SBIR Phase I | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1,015,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $714,666 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Diagnostic assay for congenital Chagas disease | $303,250 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $876,394 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $123,606 | |
| Federal grant | Department of Health and Human Services · Phase II · Peptide-based ELISA for laboratory diagnosis of sarcoidosis | $978,191 | |
| Federal grant | Department of Health and Human Services · Phase II · Biomarker-Based Test of Cure for Chagas Disease | $906,016 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 153 | BIOSENSICS LLC | $3.5M | — |
| 154 | PEDIASTENT LLC | $3.4M | — |
| 155 | SPINEOLOGY INC | $3.4M | $48M |
| 156 | KEPHERA DIAGNOSTICS LLC | $3.3M | — |
| 157 | INNOVATIVE DESIGN LABS INC | $3.3M | — |
| 158 | AUTONOMUS MEDICAL TECHNOLOGIES, INC. | $3.3M | — |
| 159 | DIGIRAD CORP | $3.3M | $3.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods, Diagnostic Instruments, And Kits For Detecting Diseasesapplication
- Method For Detecting Lyme Diseaseapplication
- Methods, Diagnostic Instruments, And Kits For Detecting Diseasesapplication
- Methods, Systems, Microplates, Uses, Compositions, And Kits For Detecting Infectious Diseasesapplication
- Methods, Diagnostic Instruments, And Kits For Detecting Diseasesapplication
- Methods, Systems, Microplates, Uses, Compositions, And Kits For Detecting Infectious Diseasesapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.